Please cite this article in press as: Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014), http://dx. doi. org/10. 1016/j. bbr. 2014. 07. 016ARTICLE IN PRESSG Model BBR 9035 1-22 A. L. Halberstadt / Behavioural Brain Research xxx (2014) xxx-xxx 21 [383] Di Martino A, Scheres A, Margulies D, Kelly A, Uddin L, Shehzad Z, et al. Functional connectivity of human striatum: a resting state f MRI study. Cereb Cortex 2008;18:2735-47. [384] Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsy-chopharmacology 2007;32:1876-87. [385] Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001;156:194-215. [386] Sipes TE, Geyer MA. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 1997;761:97-104. [387] Prentiss DW, Morgan FP. Anhalonium lewinii (mescal buttons): a study of the drug, with especial reference to its physiological action upon man, with report of experiments. Ther Gaz 1895;19:577-85. [388] Mitchell SW. Remarks on the effects of Anhelonium lewinii (the mescal but-ton). Br Med J 1896;2:1625-9. [389] Ellis H. Mescal: a new artiﬁcial paradise. Annu Rep Smithsonian Inst 1898:537-48. [390] Ellis H. Mescal: a study of a divine plant. Pop Sci Monthly 1902;61:52-71. [391] Knauer A, Maloney WJMA. A preliminary note on the psychic action of mescalin, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 1913;40:425-36. [392] Klüver H. Mescal visions and edetic vision. Am J Psychol 1926;37:502-15. [393] Klüver H. Mescal—the divine plant and its psychological effects. London: Kegan Paul; 1928. [394] Siegel RK, Jarvik ME. Drug-induced hallucinations in animals and man. In: Siegel RK, West LS, editors. Hallucinations: behavior, experience and theory. New York: John Wiley and Sons; 1975. p. 81-161. [395] Sacks O. Migraine. London: Picador; 1995. [396] Heron W, Doane BK, Scott TH. Visual disturbances after prolonged perceptual isolation. Can J Psychol 1956;10:13-8. [397] Becker C, Elliott MA. Flicker-induced color and form: interdependen-cies and relation to stimulation frequency and phase. Conscious Cogn 2006;15:175-96. [398] Allefeld C, Pütz P, Kastner K, Wackermann J. Flicker-light induced visual phe-nomena: frequency dependence and speciﬁcity of whole percepts and percept features. Conscious Cogn 2011;20:1344-62. [399] Knoll M, Kugler J, Eichmeier J, Höffer O. Note on the spectroscopy of subjective light patterns, Journal of. Anal Psychol 1962;7:55-69. [400] Horowitz MJ, Adams JE, Rutkin BB. Visual imagery on brain stimulation. Arch Gen Psychiatry 1968;19:469-86. [401] Ermentrout GB, Cowan JD. A mathematical theory of visual hallucination patterns. Biol Cybern 1979;34:137-50. [402] Tass P. Oscillatory cortical activity during visual hallucinations. J Biol Phys 1997;23:21-66. [403] Bressloff PC, Cowan JD, Golubitsky M, Thomas PJ, Wiener MC. Geometric visual hallucinations Euclidean symmetry and the functional architecture of striate cortex. Philos Trans R Soc Lond B Biol Sci 2001;356:299-330. [404] Bressloff PC, Cowan JD, Golubitsky M, Thomas PJ, Wiener MC. What geo-metric visual hallucinations tell us about the visual cortex. Neural Comput 2002;14:473-91. [405] Baker TI, Cowan JD. Spontaneous pattern formation and pinning in the pri-mary visual cortex. J Physiol (Paris) 2009;103:52-68. [406] López-Giménez JF, Vilaró MT, Palacios JM, Mengod G. Mapping of 5-HT 2A receptors and their m RNA in monkey brain: [3H]MDL100,907 autoradiog-raphy and in situ hybridization studies. J Comp Neurol 2001;429:571-89. [407] Watakabe A, Komatsu Y, Sadakane O, Shimegi S, Takahata T, Higo N, et al. Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and their bidirectional modulatory effects on neuronal responses. Cereb Cortex 2009;19:1915-28. [408] Moreau AW, Amar M, Le Roux N, Morel N, Fossier P. Serotoninergic ﬁne-tuning of the excitation-inhibition balance in rat visual cortical networks. Cereb Cortex 2010;20:456-67. [409] Moore RH, Hatada K, Domino EF. Effects of N,N-dimethyltryptamine on electrically evoked responses in the cat visual system and modiﬁcation by neuroleptic agents. Neuropharmacology 1976;15:535-9. [410] Moore RH, Domino EF. Modiﬁcation of the effects of LSD-25, d-amphetamine and tryptamine on electrically evoked responses in the visual sys-tem by methiothepin and octoclothepin. Arch Int Pharmacodyn Ther 1978;236:66-73. [411] Foote WE. Electrophysiological studies of d-lysergic acid diethylamide in the visual system. Neurosci Biobehav Rev 1982;6:503-7. [412] Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry 2011;69:399-406. [413] Ozeki H, Finn IM, Schaffer ES, Miller KD, Ferster D. Inhibitory stabiliza-tion of the cortical network underlies visual surround suppression. Neuron 2009;62:578-92. [414] Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an f MRI study of visual hallucinations. Nat Neu-rosci 1998;1:738-42. [415] Holroyd S, Wooten GF. Preliminary f MRI evidence of visual system dys-function in Parkinson's disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006;18:402-4. [416] Kazui H, Ishii R, Yoshida T, Ikezawa K, Takaya M, Tokunaga H, et al. Neuroimag-ing studies in patients with Charles Bonnet Syndrome. Psychogeriatrics 2009;9:77-84. [417] Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's dis-ease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45. [418] Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-21. [419] Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010;25:1399-408. [420] Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pima-vanserin, a serotonin2A receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-92. [421] Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533-40. [422] Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneﬁcial for psychosis in Parkinson's disease. Neurology 1991;41:1699-700. [423] Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997;12:610-2. [424] Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo con-trolled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75: 689-95. [425] Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 1957;66:418-34. [426] Faillace LA, Szára S. Hallucinogenic drugs: inﬂuence of mental set and setting. Dis Nerv Syst 1968;29:124-6. [427] Freedman DX. On the use and abuse of LSD. Arch Gen Psychiatry 1968;18:330-47. [428] Grof S. Realms of the human unconscious: observations from LSD research. In: Walsh RN, Vaughan F, editors. Beyond ego: transpersonal dimensions in psychology. Los Angeles, CA: Jeremy P Tarcher, Inc. ; 1980. p. 87-99. [429] De Shon HJ, Rinkel M, Solomon HC. Mental changes experimentally produced by LSD (d-lysergic acid diethylamide tartrate). Psychiatr Q 1952;26:33-53. [430] Freedman DX. LSD: the bridge from human to animal. In: Jacobs BL, edi-tor. Hallucinogens: neurochemical, behavioral, and clinical perspectives. New York: Raven Press; 1984. p. 203-26. [431] Glennon RA. Clasical hallucinogens: an introductory overview. NIDA Res Monogr 1994;146:4-32. [432] Shulgin AT, Shulgin A. PIHKAL: a chemical love story. Berkeley, CA: Transform Press; 1991. [433] Shulgin AT, Shulgin A. TIHKAL: the continuation. Berkeley, CA: Transform Press; 1997. [434] Naranjo C. The healing journey. New York: Pantheon Books; 1973. [435] Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Grif-ﬁths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl) 2012;223: 1-15. [436] Boyer EW. Dextromethophan abuse. Pediatr Emerg Care 2004;20:858-63. [437] Nicholson KL, Hayes BA, Balster RL. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 1999;146:49-59. [438] Narita M, Yoshizawa K, Nomura M, Aoki K, Suzuki T. Role of the NMDA recep-tor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol 2001;423:41-6. [439] Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efﬁcacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014, http://dx. doi. org/10. 1097/NMD. 0000000000000113 [in press]. [440] Ashby Jr CR, Edwards E, Harkins K, Wang RY. Effects of (+/-)-on medial prefrontal cortical cells: a microiontophoretic study. Brain Res 1989;498: 393-6. [441] Ashby Jr CR, Edwards E, Wang RY. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 1994;17: 173-81. [442] Boardman WK, Goldstone S, Lhamon WT. Effects of lysergic acid diethylamide (LSD) on the time sense of normals; a preliminary report. AMA Arch Neurol Psychiatry 1957;78:321-4. [443] Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 2008;199:77-88. [444] Knoll M, Krugler J. Subjective light pattern spectroscopy in the encephalo-graphic frequency range. Nature 1959;184:1823-4. [445] Marek GJ. Activation of adenosine1 (A1) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. Neuropharmacology 2009;56:1082-7. [446] Miyashita Y. Inferior temporal cortex: where visual perception meets mem-ory. Ann Rev Neurosci 1993;16:245-63. [447] Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci 2002;22:2843-54. 2379 2380238123822383238423852386238723882389239023912392239323942395239623972398239924002401240224032404240524062407240824092410241124122413241424152416241724182419242024212422242324242425242624272428242924302431243224332434243524362437243824392440244124422443244424452446244724482449245024512452245324542455245624572458245924602461246224632464 24652466246724682469247024712472247324742475247624772478247924802481248224832484248524862487248824892490249124922493249424952496249724982499250025012502250325042505250625072508250925102511251225132514251525162517251825192520252125222523252425252526 2527 252825292530253125322533253425352536253725382539254025412542254325442545254625472548